Recent updates on the management of autoimmune hepatitis
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Autoimmune hepatitis (AIH) is an immunoinflammatory chronic liver disease with dynamic and rather heterogeneous disease manifestations. A trend of increasing prevalence of AIH has been observed worldwide, along with a relative increase in the percentage of male patients. AIH is characterized and diagnosed based on serum biochemistry and liver histology: elevated aminotransferases and serum immunoglobulin G (IgG), the presence of serum anti-nuclear antibody or anti-smooth muscle antibody, and interface lympho-plasmacytic hepatitis. Clinical manifestations differ among disease subtypes with distinct time-frames, i.e., AIH with a chronic insidious onset, and acute-onset AIH (the diagnosis of which is often challenging due to the lack of typical serum findings). The absence of disease-specific biomarkers or histological findings may expand the disease phenotype into drug-induced AIH-like liver injury. Corticosteroids and azathioprine are recommended first-line treatments for AIH. The complete normalization of aminotransferases and serum IgG is an essential treatment response to ensure long-term overall survival. An incomplete response or intolerance to these drugs is considered an indication for second-line treatment, especially with mycophenolate mofetil. Lifelong maintenance treatment is required for the majority of patients, but the few who achieve prolonged and stringent biochemical remission with lower alanine aminotransferase and IgG within the normal range may be able to discontinue the medications. In the future, the quality of life of AIH patients should be managed by personalized medicine, including the appropriate selection and dosing of first-line therapy and perhaps alternating with potential therapeutics, and the prediction of the success of treatment withdrawal.
Abstract
Autoimmune hepatitis (AIH) is an immunoinflammatory chronic liver disease with dynamic and rather heterogeneous disease manifestations. A trend of increasing prevalence of AIH has been observed worldwide, along with a relative increase in the percentage of male patients. AIH is characterized and diagnosed based on serum biochemistry and liver histology: elevated aminotransferases and serum immunoglobulin G (IgG), the presence of serum anti-nuclear antibody or anti-smooth muscle antibody, and interface lympho-plasmacytic hepatitis. Clinical manifestations differ among disease subtypes with distinct time-frames, i.e., AIH with a chronic insidious onset, and acute-onset AIH (the diagnosis of which is often challenging due to the lack of typical serum findings). The absence of disease-specific biomarkers or histological findings may expand the disease phenotype into drug-induced AIH-like liver injury. Corticosteroids and azathioprine are recommended first-line treatments for AIH. The complete normalization of aminotransferases and serum IgG is an essential treatment response to ensure long-term overall survival. An incomplete response or intolerance to these drugs is considered an indication for second-line treatment, especially with mycophenolate mofetil. Lifelong maintenance treatment is required for the majority of patients, but the few who achieve prolonged and stringent biochemical remission with lower alanine aminotransferase and IgG within the normal range may be able to discontinue the medications. In the future, the quality of life of AIH patients should be managed by personalized medicine, including the appropriate selection and dosing of first-line therapy and perhaps alternating with potential therapeutics, and the prediction of the success of treatment withdrawal.
참고문헌 (75)
- Mack CL, "Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases", Hepatology, 72, pp.671~722 (2020)
- Kim BH, "Populationbased prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea", PLoS One, 12, pp.e0182391~ (2017)
- Takahashi A, "Autoimmune hepatitis in Japan: trends in a nationwide survey", J Gastroenterol, 52, pp.631~640 (2017)
- Tanaka A, "Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan", Hepatol Res, 49, pp.881~889 (2019)
- Lee YM, "Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women", J Gastroenterol Hepatol, 16, pp.1384~1389 (2001)
- Hurlburt KJ, "Prevalence of autoimmune liver disease in Alaska natives", Am J Gastroenterol, 97, pp.2402~2407 (2002)
- Werner M, "idemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study", Scand J Gastroenterol, 43, pp.1232~1240 (2008)
- Danielsson Borssén Å, "Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis", Scand J Gastroenterol, 52, pp.1022~1028 (2017)
- Johnson PJ, "Meeting report: International Autoimmune Hepatitis Group", Hepatology, 18, pp.998~1005 (1993)
- Alvarez F, "International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis", J Hepatol, 31, pp.929~938 (1999)
- Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
- Czaja AJ, "Performance parameters of the diagnostic scoring systems for autoimmune hepatitis", Hepatology, 48, pp.1540~1548 (2008)
- Boberg KM, "Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue", J Hepatol, 54, pp.374~385 (2011)
- Yatsuji S, "Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease:is the International Autoimmune Hepatitis Group scoring system useful?", J Gastroenterol, 40, pp.1130~1138 (2005)
- Gurung A, "Histologic features of autoimmune hepatitis: a critical appraisal", Hum Pathol, 82, pp.51~60 (2018)
- Tucker SM, "Hyaline droplets in Kupffer cells: a novel diagnostic clue for autoimmune hepatitis", Am J Surg Pathol, 39, pp.772~778 (2015)
- Nguyen Canh H, "Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients", J Clin Pathol, 70, pp.961~969 (2017)
- Stravitz RT, "Autoimmune acute liver failure: proposed clinical and histological criteria", Hepatology, 53, pp.517~526 (2011)
- De Luca-Johnson J, "Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease", Dig Dis Sci, 61, pp.2710~2720 (2016)
- Takahashi A, "Non-alcoholic fatty liver disease in patients with autoimmune hepatitis", JGH Open, 2, pp.54~58 (2018)
- Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.756~768 (2017)
- Wu S, "Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis", Hepatol Int, 13, pp.91~101 (2019)
- Hartl J, "Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis", J Hepatol, 65, pp.769~775 (2016)
- Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)
- Migita K, "Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis", Medicine (Baltimore), 97, pp.E13450~ (2018)
- Czaja AJ, "Acute and acute severe (fulminant) autoimmune hepatitis", Dig Dis Sci, 58, pp.897~914 (2013)
- Kim BH, "Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study", J Gastroenterol Hepatol, 28, pp.128~134 (2013)
- Muratori P, "Clinical and prognostic implications of acute onset of autoimmune hepatitis: an Italian multicentre study", Dig Liver Dis, 50, pp.698~702 (2018)
- Joshita S, "Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey", J Gastroenterol, 53, pp.1079~1088 (2018)
- Yeoman AD, "Prognosis of acute severe autoimmune hepatitis (ASAIH): the role of corticosteroids in modifying outcome", J Hepatol, 61, pp.876~882 (2014)
- Moenne-Loccoz R, "Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis", J Hepatol, 65, pp.444~446 (2016)
- Rahim MN, "Acute severe autoimmune hepatitis: corticosteroids or liver ttransplantation?", Liver Transpl, 25, pp.946~959 (2019)
- Zachou K, "Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis", Hepatol Res, 49, pp.96~104 (2019)
- Yasui S, "Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure", Hepatol Res, 42, pp.42~50 (2012)
- Zabron A, "Clinical and prognostic associations of liver volume determined by computed tomography in acute liver failure", Liver Int, 38, pp.1592~1601 (2018)
- Karkhanis J, "Steroid use in acute liver failure", Hepatology, 59, pp.612~621 (2014)
- Anand L, "Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy", Hepatology, 70, pp.587~596 (2019)
- Weber S, "Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis", Liver Int, 39, pp.1906~1917 (2019)
- Liu ZX, "Immune-mediated drug-induced liver disease", Clin Liver Dis, 6, pp.755~774 (2002)
- Chalasani N, "Features and outcomes of 899 patients with druginduced liver injury: the DILIN prospective study", Gastroenterology, 148, pp.1340~1352.e7 (2015)
- Boer YS, "Features of autoimmune hepatitis in patients with drug-induced liver injury", Clin Gastroenterol Hepatol, 15, pp.103~112.e2 (2017)
- Robles-Diaz M, "Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury", Gastroenterology, 147, pp.109~118.e5 (2014)
- Björnsson E, "Drug-induced autoimmune hepatitis: clinical characteristics and prognosis", Hepatology, 51, pp.2040~2048 (2010)
- Zen Y, "Hepatotoxicity of immune checkpoint inhibitors:a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury", Mod Pathol, 31, pp.965~973 (2018)
- Nishida N, "Liver damage related to immune checkpoint inhibitors", Hepatol Int, 13, pp.248~252 (2019)
- Gatselis NK, "Molecular diagnostic testing for primary biliary cholangitis", Expert Rev Mol Diagn, 16, pp.1001~1010 (2016)
- Chazouillères O, "Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy", Hepatology, 28, pp.296~301 (1998)
- Bonder A, "Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome", Clin Gastroenterol Hepatol, 9, pp.609~612 (2011)
- Czaja AJ, "Cholestatic phenotypes of autoimmune hepatitis", Clin Gastroenterol Hepatol, 12, pp.1430~1438 (2014)
- Simoes CC, "Direct-acting antiviral treatment of patients with hepatitis C resolves serologic and histopathologic features of autoimmune hepatitis", Hepatol Commun, 3, pp.1113~1123 (2019)
- Yoshizawa K, "Long-term outcome of Japanese patients with type 1autoimmune hepatitis", Hepatology, 56, pp.668~676 (2012)
- Choi J, "Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country", Liver Int, 39, pp.985~994 (2019)
- Lamers MM, "Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials", J Hepatol, 53, pp.191~198 (2010)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: autoimmune hepatitis", J Hepatol, 63, pp.971~1004 (2015)
- Moriyama T, "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity", Nat Genet, 48, pp.367~373
- Pape S, "Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 17, pp.2068~2075 (2019)
- Vierling JM, "Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases guidelines", Hepatology, 72, pp.753~769 (2020)
- American Gastroenterological Association, "American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders", Gastroenterology, 125, pp.937~940 (2003)
- Long MD, "Bone health in a tertiary-care gastroenterology and hepatology population", Dig Dis Sci, 55, pp.2263~2269 (2010)
- Suzuki Y, "Guidelines on the management and treatment of glucocorticoidinduced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update", J Bone Miner Metab, 32, pp.337~350 (2014)
- Efe C, "Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis", Dig Dis Sci, 59, pp.3035~3042 (2014)
- Ebadi M, "Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepati", Aliment Pharmacol Ther, 49, pp.173~182 (2019)
- De Lemos-Bonotto M, "A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment", Eur J Gastroenterol Hepatol, 30, pp.212~216 (2018)
- Nicoll AJ, "Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels", Aliment Pharmacol Ther, 49, pp.1314~1322 (2019)
- Srivastava S, "Psychological stress is associated with relapse in type 1 autoimmune hepatitis", Liver Int, 30, pp.1439~1447 (2010)
- van Gerven NM, "Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission", J Hepatol, 58, pp.141~147 (2013)
- Hartl J, "Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis", J Hepatol, 62, pp.642~646 (2015)
- Younossi ZM, "Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States", Clin Gastroenterol Hepatol, pp.064~ (2020)[DOI]
- Heinemann M, "Longterm survival after liver transplantation for autoimmune hepatitis: results from the European Liver Transplant Registry", Liver Transpl, 26, pp.866~877 (2020)
- Hayashi M, "Allograft rejection after liver transplantation for autoimmune liver diseases", Liver Transpl Surg, 4, pp.208~214 (1998)
- Milkiewicz P, "Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors", Transplantation, 70, pp.477~480 (2000)
- Tanaka A, "Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016", Hepatol Int, 10, pp.909~915 (2016)
- Takahashi A, "Health-related quality of life in patients with autoimmune hepatitis: a questionnaire survey", PLoS One, 13, pp.e0204772~ (2018)
- ong LL, "The impact of autoimmune hepatitis and its treatment on health utility", Hepatology, 68, pp.1487~1497 (2018)
- Janik MK, "Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: a prospective, singlecentre study", Liver Int, 39, pp.215~221 (2019)